Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data

TARGET AUDIENCE:
This activity is designed to meet the educational needs of Urologists and Urologic Oncologists
PROGRAM OVERVIEW:
Join key thought leaders in the world of bladder cancer " Drs. Sam Chang and Shilpa Gupta " as they review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy. Our experts will also provide the tools necessary for effective therapeutic sequencing of intravesical chemotherapy, BCG, platinum chemotherapy, ICIs, and surgical modalities, as well as adaptive integration of novel combinatorial regimens. Finally, the panel will offer expert insights for anticipating and managing immune-related adverse events (irAEs) in patients receiving ICIs.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
• Appraise the expanding clinical trial evidentiary base in NMIBC and MIBC, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment.
• Examine the evolving bladder cancer management calculus in non-metastatic disease, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating intravesical chemotherapy, BCG, platinum chemotherapy, immune checkpoint inhibitors, and surgical modalities.
• Design evidence-supported treatment plans for patients with bladder cancer, both in NMIBC and as neoadjuvant/adjuvant therapy in MIBC, by effectively integrating consensus guideline recommendations with patient-centric factors (i.e., performance status, renal function, PD-L1 expression, cytopathology, urinary markers, etc.).
• Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.